Tailoring Combination Oral Contraceptives to the Individual Woman

Archer, David F.; Lasa, I Lete

doi:10.1089/jwh.2010.2199

Cited by 6 publications

(3 citation statements)

References 98 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although literature suggests that mainly the progestin component of HRT increases BC risk (23)(24)(25), a systematic review reported no increased risk after progestin-only OC use (26). Moreover, although synthetic hormone levels in OCs are higher than in HRT (27), we found no increased BC risk for women using OCs as HRT.…”

Section: Discussioncontrasting

confidence: 78%

Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure

Krul

Winden

Aleman

et al. 2017

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 78%

Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure

Krul

Winden

Aleman

et al. 2017

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Progestogens can bind to various types of receptors including those for estrogens, androgens, glucocorticoids, and mineralocorticoids, as well as progestogens, and hence, they are involved in a range of different biological activities. 33 Given that some PMS symptoms occur when there is a reduction in the plasma levels of progesterone produced by the corpus luteum, as a consequence of its metabolites pregnenolone and allopregnanolone, it was thought that exogenous progesterone or progestogen might have a beneficial effect on women with PMS. 34 …”

Section: Effect Of Chc Progestogens On Pmsmentioning

confidence: 99%

Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review

Lete

Lapuente

2016

OAJC

View full text Add to dashboard Cite

Premenstrual syndrome and its most severe form, premenstrual dysphoric disorder (PMDD), are two well-defined clinical entities that affect a considerable number of women. Progesterone metabolites and certain neurotransmitters, such as gamma-aminobutyric acid and serotonin, are involved in the etiology of this condition. Until recently, the only treatment for women with PMDD was psychoactive drugs, such as selective serotonin reuptake inhibitors. Several years ago, there has been evidence of the beneficial role of combined hormonal contraceptives in controlling PMDD symptoms. Oral combined hormonal contraceptives that contain drospirenone in a 24+4-day regimen are the only drugs that have been approved by US Food and Drug Administration for the treatment of PMDD, but there is scientific evidence that other agents, with other formulations and regimens, could also be effective for the treatment of this condition. However, it remains unclear whether the beneficial effect of combined hormonal contraceptives is associated with the type of estrogen or progestogen used or the treatment regimen.

show abstract

“…7,8,11,12 Because publicity about venous thromboembolism risks and selective prescribing of specific products 16 are known or suspected to have occurred while the studies were ongoing, serious concern exists that these database deficiencies may have obscured differential misclassification of exposure and outcomes and unequal distribution of confounders between exposure groups. Consequently, undetected biases could have resulted in inflated estimates of venous thromboembolism risk.…”

Section: Background: Data On Venous Thromboembolismmentioning

confidence: 99%

Combined Hormonal Contraceptives and Venous Thromboembolism

Raymond

Burke

Espey

2012

Obstetrics & Gynecology

View full text Add to dashboard Cite

To date, 13 studies have provided data on the risk of venous thromboembolism associated with combined oral contraceptives containing drospirenone or the norelgestromin-containing contraceptive patch. The studies varied in their conclusions about whether these methods are associated with higher risks than combined oral contraceptives containing other progestins: the primary reported measures of association (adjusted odds ratios, incidence rate ratios, or hazard ratios) ranged from 0.9 to 3.3. All of the studies had weaknesses in population selection, data validity or completeness, or analysis that may have led to biased or spurious findings. Venous thromboembolism is rare; if the contraceptive methods of interest do confer a higher risk of thromboembolism, only an additional 5-10 per 10,000 users per year would be affected. The important message for patients, clinicians, and policy makers is that the benefits of all contraceptive methods markedly outweigh their risks, primarily because they prevent pregnancy, an inherently hazardous condition. Product labels for hormonal contraceptives should emphasize their substantial health benefits and established safety.

show abstract

Tailoring Combination Oral Contraceptives to the Individual Woman

Abstract: Appropriate counseling to raise awareness of the specific characteristics of the different COC options available may optimize adherence and patient acceptability.

Cited by 6 publications

References 98 publications

Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure

Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure

Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review

Combined Hormonal Contraceptives and Venous Thromboembolism

Contact Info

Product

Resources

About